Roche Holding AG RHHBY:OTCQX International Premier (Depositary Receipt)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
35.66 0.46   1.31%3.15%615,7491.6M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. As of 03:59 PM ET 10/8/2014

Latest News Headlines for Roche Holding AG

FDA Grants Priority Review for Genentech's Lucentis in Diabetic Retinopathy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--October 08, 2014-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis(R) (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015.

Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market

Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient. MOUNTAIN VIEW, Calif., Sept. 30, 2014 /PRNewswire/ -- Based on its recent analysis of the oncology tissue diagnostics market, Frost & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Adherence to strict quality practices along with a focus on innovation and improving patient safety have made Ventana a global leader in tissue-based cancer diagnostic solutions for patients worldwide.

Genentech's Investigational Combination of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit to People With Advanced Melanoma Over Zelboraf Alone

-- Cobimetinib plus Zelboraf reduced the risk of disease worsening by half compared to Zelboraf alone -- Phase III coBRIM study results will be presented today during the

View more recent headlines

Company Background

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It belongs to the Roche Group that operates through subsidiaries and associated companies. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. It operates worldwide containing the United States, Western Europe, Japan, Latin America and Asia-Pacific, among others. Diagnostics include five business areas: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It operates in five geographical regions: Europe, Middle East and Africa (EMEA); North America; Asia-Pacific; Latin America, and Japan. In September 2014, it accepted for payment of all shares of InterMune Inc. through its wholly owned subsidiary Klee Acquisition Corporation.

http://www.roche.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open35.115
Previous Close35.20
Day High35.725
Day Low35.05
52 Week High2/28/2014 | 38.71
52 Week Low10/9/2013 | 31.75
% Off 52 Week High-7.88%
% Off 52 Week Low12.31%
Beta (5 Yr)0.6
Volatility Avg10/7/2014 | 17.21
10-Day Avg. Volume1,628,744
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | 1.63
P/E Ratio6/30/2014 | 21.6
Market CapLarge Cap | 196.7B
Shares Outstanding5.52B
Float5.6B

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield3.15%
Ex-Date3/6/2014
Dividend Announcement2/27/2014
Date of Record3/10/2014
Payable$1.109 - ANN
Payable Date4/22/2014

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short--
Short Ratio--
Short % of Float--
As of --

Peers Information HelpRHHBY Roche Holding AG vs. Peers

Peers 
RHHBY
Roche Holding AG
0.28%
Johnson & Johnson
11.79%
Abbott Laboratories
8.17%
Merck & Co., Inc.
16.80%
Bristol-Myers Squibb Co
-6.36%
RHHBY
Roche Holding AG
3.11%
Johnson & Johnson
2.73%
Abbott Laboratories
2.12%
Merck & Co., Inc.
3.01%
Bristol-Myers Squibb Co
2.89%
RHHBY
Roche Holding AG
1.31%
Johnson & Johnson
2.46%
Abbott Laboratories
1.64%
Merck & Co., Inc.
2.94%
Bristol-Myers Squibb Co
0.88%
Compare these stocks